| Autor: |
Nicole DePasquale, Jamie A. Green, Patti L. Ephraim, Sarah Morton, Sarah B. Peskoe, Clemontina A. Davenport, Dinushika Mohottige, Lisa McElroy, Tara S. Strigo, Felicia Hill-Briggs, Teri Browne, Jonathan Wilson, LaPricia Lewis-Boyer, Ashley N. Cabacungan, L. Ebony Boulware |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Kidney Medicine, Vol 4, Iss 9, Pp 100521- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2590-0595 |
| DOI: |
10.1016/j.xkme.2022.100521 |
| Popis: |
Rationale & Objective: Choosing from multiple kidney failure treatment modalities can create decisional conflict, but little is known about this experience before decision implementation. We explored decisional conflict about treatment for kidney failure and its associated patient characteristics in the context of advanced chronic kidney disease (CKD). Study Design: Cross-sectional study. Setting & Participants: Adults (N = 427) who had advanced CKD, received nephrology care in Pennsylvania-based clinics, and had no history of dialysis or transplantation. Predictors: Participants’ sociodemographic, physical health, nephrology care/knowledge, and psychosocial characteristics. Outcomes: Participants’ results on the Sure of myself; Understand information; Risk-benefit ratio; Encouragement (SURE) screening test for decisional conflict (no decisional conflict vs decisional conflict). Analytical Approach: We used multivariable logistic regression to quantify associations between aforementioned participant characteristics and decisional conflict. We repeated analyses among a subgroup of participants at highest risk of kidney failure within 2 years. Results: Most (76%) participants reported treatment-related decisional conflict. Participant characteristics associated with lower odds of decisional conflict included complete satisfaction with patient–kidney team treatment discussions (OR, 0.16; 95% CI, 0.03-0.88; P = 0.04), attendance of treatment education classes (OR, 0.38; 95% CI, 0.16-0.90; P = 0.03), and greater treatment-related decision self-efficacy (OR, 0.97; 95% CI, 0.94-0.99; P < 0.01). Sensitivity analyses showed a similarly high prevalence of decisional conflict (73%) and again demonstrated associations of class attendance (OR, 0.26; 95% CI, 0.07-0.96; P = 0.04) and decision self-efficacy (OR, 0.95; 95% CI, 0.91-0.99; P = 0.03) with decisional conflict. Limitations: Single-health system study. Conclusions: Decisional conflict was highly prevalent regardless of CKD progression risk. Findings suggest efforts to reduce decisional conflict should focus on minimizing the mismatch between clinical practice guidelines and patient-reported engagement in treatment preparation, facilitating patient–kidney team treatment discussions, and developing treatment education programs and decision support interventions that incorporate decision self-efficacy–enhancing strategies. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
